Bone Mineral Density

Older adults with subclinical hypothyroidism assigned 1 year of levothyroxine therapy experienced no adverse changes in any bone parameters compared with similar adults assigned placebo, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

Older adults who discontinue denosumab are at greater risk for major osteoporotic fractures and multiple vertebral fractures than those who persist with treatment, according to findings from a real-world database analysis published in Bone.

ATLANTA — The 2019 iteration of the ACR/ARP Great Debate tackled the issue of whether anabolic therapies are appropriate for patients with glucocorticoid-induced osteoporosis.

Postmenopausal women who report sleeping less than 5 hours per night are more likely to develop low bone mineral density at all major sites and are at increased risk for osteoporosis at the hip and spine, according to findings published in the Journal of Bone and Mineral Research.

WASHINGTON — A class of endocrine-disrupting chemicals known as PFAS may work as an “environmental trigger” to drive multiple adverse endocrine health effects, including obesity, thyroid dysfunction and low bone mineral density, although researchers caution that more studies on potential associations are needed.

Severe energy restriction with a total meal replacement diet among postmenopausal women with obesity induced greater weight loss and approximately 1.5-fold as much loss of whole-body lean mass and thigh muscle area compared with moderate energy restriction over 12 months; however, researchers also observed a greater decrease in hip bone mineral density with severe energy restriction, according to findings published in JAMA Network Open

SAN DIEGO — Taking a ‘holiday’ from many osteoporosis drugs can frequently negate gains in bone density, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

Adults with obesity who underwent Roux-en-Y gastric bypass experienced an improvement in bone material strength in the year after surgery despite an increase in bone turnover markers and decrease in bone mineral density, according to findings published in Bone.

SAN DIEGO — Understanding which drugs and drug classes contribute to adverse bone effects, including bone loss and fractures, may be extremely useful for rheumatologists and their patients, according to a presentation at the 2019 Congress of Clinical Rheumatology West.

Among a cohort of postmenopausal women randomly assigned to romosozumab or alendronate, larger improvements in bone mineral density and bone strength in the lumbar spine were observed for those taking romosozumab, according to findings presented at the American Society of Bone and Mineral Research annual meeting.